A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer

James C.M. Ho, E. H. Tan, S. S. Leong, C. H. Wang, Y. Sun, R. Li, M. I.A. Wahid, A. Jusuf, M. Liao, Z. Guan, P. Handoyo, J. S. Huang, V. Chan, G. Luna, K. W.T. Tsang, W. K. Lam*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

6 Scopus citations

Abstract

Aims: To evaluate the efficacy and safety of docetaxel-cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Methods: Chemotherapy-naïve patients with histologically confirmed TNM stage III or IV NSCLC were recruited from 12 Asian trial centers. Patients received docetaxel (75 mg/m2) and cisplatin (75 mg/m2) every 3 weeks for 6 cycles. Results: 130 of 146 patients were evaluable for efficacy (60% stage IV). Three complete and 58 partial responses were observed (overall response rate: 46.9%; 95% Cl: 38.3-55.5%). Median time to progression was 6.9 months and median survival was 14.0 months; 1-year survival was 59.5%. Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 69.2%, 6.2% and 18.5% of patients, respectively. Grade 3/4 vomiting was observed in 13.7% and grade 3/4 neurosensory effects were observed in 2.7% of patients. There was one case of treatment-related death due to sepsis. Conclusion: Docetaxel-cisplatin is an effective and well-tolerated treatment in Asian patients with NSCLC.

Original languageEnglish
Pages (from-to)796-803
Number of pages8
JournalRespiratory Medicine
Volume97
Issue number7
DOIs
StatePublished - 01 07 2003
Externally publishedYes

Keywords

  • Cisplatin
  • Docetaxel
  • First-line
  • Non-small cell lung cancer

Fingerprint

Dive into the research topics of 'A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this